Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris  A randomized controlled trial

Meghana D; Laxminarayana Kamath; Revathi T N

doi:10.5455/njppp.2021.10.07180202022082020

2023, Vol: 13, Issue: 3

13/3Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Authorship Declaration

« Previous Article

Original Research

Natl J Physiol Pharm Pharmacol. 2021; 11(1): 13-16

doi: 10.5455/njppp.2021.10.07180202022082020

Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris A randomized controlled trial

Meghana D, Laxminarayana Kamath, Revathi T N.

Abstract
Background: Dermatophyte infections are very common and they manifest as tinea corporis/cruris. Among the various topical antifungal drugs available, the first option being terbinafine and new generation azoles as sertaconazole professes superior activity.

Aim and Objective: The objective of the study was to evaluate efficacy and safety of topical terbinafine versus topical sertaconazole in tinea cruris patients.

Materials and Methods: We conducted a randomized control trial from May 2019 to September 2019 in the Department of Dermatology, Bangalore Medical College and Research Institute. Over 60 patients with tinea cruris randomly divided into two groups of 30 each. Group A applied topical 1% terbinafine cream and Group B applied topical 2% sertaconazole cream for a period of 4 weeks. Follow-up visit of patients was at 2 and 4 weeks to assess efficacy parameters (mycological and clinical cure) and safety assessment done by recording adverse reactions.

Results: Thirty patients were analyzed in each group. About 98.3% in the terbinafine group and 99.4% in the sertaconazole group showed significant improvement in signs and symptoms from baseline to 4 weeks (P < 0.001). The mean difference of the total score of all parameters (baseline to 4 weeks) for the terbinafine group was 4.06 ± 0.79 and the sertaconazole group was 4.60 ± 0.95, respectively. Mycological cure was achieved by all patients. Both drugs were well tolerated. No serious adverse drug events in both the groups.

Conclusion: Terbinafine was equal in efficacy and safety to newer azole sertaconazole in treating patients with tinea cruris. However, sertaconazole has showed a better response to
therapy as compared to terbinafine.

Key words: Dermatophyte Infections; Tinea Cruris; Topical Antifungals; Sertaconazole; Terbinafine

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Meghana D Articles by Laxminarayana Kamath Articles by Revathi T N
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

D M, Kamath L, N RT. Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris A randomized controlled trial. Natl J Physiol Pharm Pharmacol. 2021; 11(1): 13-16. doi:10.5455/njppp.2021.10.07180202022082020

Web Style

D M, Kamath L, N RT. Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris A randomized controlled trial. https://www.njppp.com/?mno=96512 [Access: March 02, 2023]. doi:10.5455/njppp.2021.10.07180202022082020

AMA (American Medical Association) Style

D M, Kamath L, N RT. Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris A randomized controlled trial. Natl J Physiol Pharm Pharmacol. 2021; 11(1): 13-16. doi:10.5455/njppp.2021.10.07180202022082020

Vancouver/ICMJE Style

D M, Kamath L, N RT. Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris A randomized controlled trial. Natl J Physiol Pharm Pharmacol. (2021), [cited March 02, 2023]; 11(1): 13-16. doi:10.5455/njppp.2021.10.07180202022082020

Harvard Style

D, M., Kamath, . L. & N, . R. T. (2021) Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris A randomized controlled trial. Natl J Physiol Pharm Pharmacol, 11 (1), 13-16. doi:10.5455/njppp.2021.10.07180202022082020

Turabian Style

D, Meghana, Laxminarayana Kamath, and Revathi T N. 2021. Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris A randomized controlled trial. National Journal of Physiology, Pharmacy and Pharmacology, 11 (1), 13-16. doi:10.5455/njppp.2021.10.07180202022082020

Chicago Style

D, Meghana, Laxminarayana Kamath, and Revathi T N. "Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris A randomized controlled trial." National Journal of Physiology, Pharmacy and Pharmacology 11 (2021), 13-16. doi:10.5455/njppp.2021.10.07180202022082020

MLA (The Modern Language Association) Style

D, Meghana, Laxminarayana Kamath, and Revathi T N. "Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris A randomized controlled trial." National Journal of Physiology, Pharmacy and Pharmacology 11.1 (2021), 13-16. Print. doi:10.5455/njppp.2021.10.07180202022082020

APA (American Psychological Association) Style

D, M., Kamath, . L. & N, . R. T. (2021) Evaluation of efficacy and safety of topical 1% terbinafine versus topical 2% sertaconazole in patients with tinea cruris A randomized controlled trial. National Journal of Physiology, Pharmacy and Pharmacology, 11 (1), 13-16. doi:10.5455/njppp.2021.10.07180202022082020

Author Login Reviewer Login About Publisher Editorial Policies Peer Review Policy Editorial & Peer Review Process Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information



Copyright © 2023 National Journal of Physiology, Pharmacy and Pharmacology All Rights Reserved. Subject to change without notice from or liability to National Journal of Physiology, Pharmacy and Pharmacology. For best results, please use Internet Explorer or Google Chrome	Contact Information Publisher publishernjppp@gmail.com Editorial query editornjppp1@gmail.com MOB - 8780040272

Contact Information

How to cite this article